



ACQUISITION OF VERSUM MATERIALS

Merck KGaA, Darmstadt, Germany

Marcus Kuhnert, CFO

April 12, 2019



Disclaimer

Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the group of companies affiliated with Merck KGaA, Darmstadt, Germany operates under individual business names (EMD Serono, Millipore Sigma, EMD Performance Materials). To reflect such fact and to avoid any misconceptions of the reader of the publication certain logos, terms and business descriptions of the publication have been substituted or additional descriptions have been added. This version of the publication, therefore, slightly deviates from the otherwise identical version of the publication provided outside the United States and Canada.

Disclaimer

Cautionary Note Regarding Forward-Looking Statements and financial indicators

This communication may include “forward-looking statements.” Statements that include words such as “anticipate,” “expect,” “should,” “would,” “intend,” “plan,” “project,” “seek,” “believe,” “will,” and other words of similar meaning in connection with future events or future operating or financial performance are often used to identify forward-looking statements. All statements in this communication, other than those relating to historical information or current conditions, are forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond control of Merck KGaA, Darmstadt, Germany, which could cause actual results to differ materially from such statements.

Risks and uncertainties include, but are not limited to: the risks of more restrictive regulatory requirements regarding drug pricing, reimbursement and approval; the risk of stricter regulations for the manufacture, testing and marketing of products; the risk of destabilization of political systems and the establishment of trade barriers; the risk of a changing marketing environment for multiple sclerosis products in the European Union; the risk of greater competitive pressure due to biosimilars; the risks of research and development; the risks of discontinuing development projects and regulatory approval of developed medicines; the risk of a temporary ban on products/production facilities or of non-registration of products due to non-compliance with quality standards; the risk of an import ban on products to the United States due to an FDA warning letter; the risks of dependency on suppliers; risks due to product-related crime and espionage; risks in relation to the use of financial instruments; liquidity risks; counterparty risks; market risks; risks of impairment on balance sheet items; risks from pension obligations; risks from product-related and patent law disputes; risks from antitrust law proceedings; risks from drug pricing by the divested Generics Group; risks in human resources; risks from e-crime and cyber attacks; risks due to failure of business-critical information technology applications or to failure of data center capacity; environmental and safety risks; unanticipated contract or regulatory issues; a potential downgrade in the rating of the indebtedness of Merck KGaA, Darmstadt, Germany; downward pressure on the common stock price of Merck KGaA, Darmstadt, Germany and its impact on goodwill impairment evaluations as well as the impact of future regulatory or legislative actions.

The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere, including the Report on Risks and Opportunities Section of the most recent annual report and quarterly report of Merck KGaA, Darmstadt, Germany. Any forward-looking statements made in this communication are qualified in their entirety by these cautionary statements, and there can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us or our business or operations. Except to the extent required by applicable law, we undertake no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

This presentation contains certain financial indicators such as EBITDA pre exceptionals, net financial debt and earnings per share pre exceptionals, which are not defined by International Financial Reporting Standards (IFRS). These financial indicators should not be taken into account in order to assess the performance of Merck KGaA, Darmstadt, Germany in isolation or used as an alternative to the financial indicators presented in the consolidated financial statements and determined in accordance with IFRS. The figures presented in this statement have been rounded. This may lead to individual values not adding up to the totals presented.

Additional Important Information and Where to Find It

This communication relates to the proposed merger transaction involving Versum and Merck KGaA, Darmstadt, Germany. In connection with the proposed merger, Versum and Merck KGaA, Darmstadt, Germany, intend to file relevant materials with the SEC, including Versum’s proxy statement on Schedule 14A (the “Proxy Statement”). This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, and is not a substitute for the Proxy Statement or any other document that Versum or Merck KGaA, Darmstadt, Germany, may file with the SEC or send to Versum’s stockholders in connection with the proposed merger. STOCKHOLDERS OF VERSUM ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER. Investors and security holders will be able to obtain the documents (when available) free of charge at the SEC’s web site, <http://www.sec.gov>, or Versum’s website at <http://investors.versummaterials.com> or by phone at 484-275-5907.

Participants in Solicitation

Versum, Merck KGaA, Darmstadt, Germany, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the holders of Versum common stock in respect of the proposed transaction. Information about the directors and executive officers of Versum is set forth in Versum’s Annual Report on Form 10-K for the fiscal year ended September 30, 2018, which was filed with the SEC on November 21, 2018, and the proxy statement for Versum’s 2019 annual meeting of stockholders, which was filed with the SEC on December 20, 2018. Information about the directors and executive officers of Merck KGaA, Darmstadt, Germany, is set forth on Schedule I of the Schedule 14A filed by Merck KGaA, Darmstadt, Germany, with the SEC on March 22, 2019. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Proxy Statement and other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available.

Merger agreement signed

TERMS & valuation



- All cash proposal at \$53 per Versum Materials share recommended by Versum Materials Board of Directors
- €5.8bn¹ Enterprise value, representing a 13.7x 2019E EV/EBITDA² multiple and an 11.6x 2019E EV/EBITDA² multiple, adjusted for full synergy run-rate

Financing



- Fully financed with cash and debt, Facilities Agreement in place
- Strong investment grade credit rating preserved
- Maintaining commitment to swift deleveraging

Regulatory Approvals



- No anticipated regulatory issues
- Regulatory process is underway, regulatory clearances expected in a timely manner
- Waiting period for HSR³ expired

Shareholder Approvals



- No shareholder vote required by our shareholders
- Subject to approval by Versum shareholders



The transaction is expected to close in H2 2019

¹Converted from USD to EUR at 1.12 EUR/USD exchange rate;

²Pro-forma calculation based on Versum: Wall Street consensus estimates for 2019E EBITDA as of April 5, 2019;

³HSR = Hart Scott Rodino Act; When HSR period is expired it is no longer a barrier to closing.

Value creating combination of two highly complementary industry leaders

Rebalancing portfolio towards high-growth markets

- Rebalances portfolio to a diversified structure with three strong business sectors
- Drive Performance Materials (PM) growth aspiration in electronic materials and double sales share of high-growth Semiconductor Solutions to ~50%¹

Strong industrial logic to capitalize on electronics growth

- Semiconductor industry subject to long-term secular growth drivers requiring highly innovative cutting-edge materials
- Creates one of the leading electronic materials players focused on the semiconductor and display industries
- Complementary capabilities increase scale, product and services depth and establish truly global presence

Financially attractive and immediately value accretive


- Compelling financial metrics: industry-leading growth and profitability profile
- ~€75m in annual cost synergies expected to be fully realized in 3rd year after closing
- Transaction expected to be EPS pre accretive in 1st year after closing, and to reported EPS in year 3

¹Sales share based on Merck KGaA, Darmstadt, Germany PM net sales for Q1 2018 – Q4 2018; Pro-forma net sales consolidates Versum Materials LTM net sales as per December 31, 2018; Versum Materials net sales as per Versum Materials' SEC Filings.


Versum Materials – A leading supplier to the electronics industry

- **Leading global supplier** of high-purity process chemicals, gases and equipment serving mainly semiconductor manufacturers
- **Established positions** in advanced deposition, specialty gases, chemical mechanical planarization² as well as delivery systems and services
- **Today headquartered in Tempe, Arizona** with **production facilities in the U.S., Korea, Taiwan and China**
- 15 production facilities worldwide
- ~ 2,300 employees
- **Track record of accelerated growth and industry leading profitability**


Sales¹ by region
FY 2018: €1,162m




Adjusted EBITDA³ by segment
FY 2018: €377m



Sales^{1,4} (€m)



Adjusted EBITDA (€m)^{1,4}



Note: Financials converted from US\$ to EUR based on average annual EUR/USD exchange rate of 2015: 1.11; 2018:1.18;

¹Source: Versum Materials investor relations materials, FY 2018 (ending September 30, 2018); ²Chemical mechanical planarization = CMP; ³Adjusted EBITDA for FY 2018 excluding Corporate segment; ⁴ CAGRs based on Versum Materials' published numbers in USD.


Combination creates a leading electronic materials player

Partner of choice



- Creating a leading electronic materials player with focus on the semiconductor and display industries and deep customer relationships
- Combined pro-forma Performance Materials annual sales ~ €3.6bn¹

Innovation



- Accelerating ability to innovate through the combination of R&D efforts
- Combine technological capabilities in order to generate novel technologies and better serve our customers

Poised for growth



- Optimally positioned to capitalize on strong long-term secular trends in the semiconductor industry, incl. the emergence of artificial intelligence, autonomous mobility, big data, internet of things, global connectivity
- Increasing diversification of end-markets

Complementary



- Complementary capabilities
- Versum Materials' business adds positions in advanced deposition, specialty gases and chemical mechanical planarization to our established presence

Deep portfolio



- Build an attractive portfolio in high value materials
- E.g. in advanced deposition materials, dielectrics, CMP slurries, and cleaning chemicals

Broadened offering



- Expanding Merck's KGaA, Darmstadt, Germany electronic materials business and tapping new growth opportunities
- Versum Materials' equipment and services business allows broader positioning along the wafer processing value chain for Merck KGaA, Darmstadt, Germany

¹Includes Performance Materials' Semiconductor Solutions business Q1 2018-Q4 2018 and Versum Materials FY 2018.


The combined business capitalizes on electronics industry growth

New markets and applications emerge daily...

- 1 Artificial intelligence
- 2 Autonomous mobility
- 3 Big data
- 4 Internet of things
- 5 Global connectivity


...driving the digital revolution as semiconductors are required for data processing and storage

Size of global data sphere in zettabytes¹



Increased chip complexity and miniaturization will drive accelerated growth for high-performance and high-purity materials

Indicative semiconductor industry roadmap




Continuous technological progress drives requirements for new materials with improved performance, quality and yield



Creates a fundamental opportunity for electronics materials companies

Combination with Versum Materials enables competitive edge, as future-critical materials will become increasingly important

Semiconductor market value¹



Electronics materials market is driven by innovation



High purity materials (CMP, deposition materials) for wafer processing play a crucial role in enabling semiconductor industry innovation

Value accretive for Merck KGaA, Darmstadt, Germany shareholders

Updated synergies

pro-forma

Enhancing sales and EBITDA pre

- Merck's KGaA, Darmstadt, Germany 2018 sales¹ increase by ~8%
- Merck's KGaA, Darmstadt, Germany 2018 EBITDA pre¹ rises by ~13%²
- Merck's KGaA, Darmstadt, Germany EBITDA pre margin expansion by ~60 bps³

value creation

Expected synergies drive value creation

- Cost synergies of ~€75m p.a.
- To be fully captured by year 3
- Immediately accretive to EPS pre
- Accretive to reported EPS including all transaction-related costs in year 3
- Transaction IRR > WACC

balance sheet

Solid financial structure preserved

- Fully financed with cash and debt (Term Loan, hybrid bond, EUR bond)
- Strong investment grade credit rating preserved
- Solid pro-forma balance sheet with estimated net debt / EBITDA pre⁴ of 3.0x and pro-forma 2.9x including 100% run-rate cost synergies

Acquisition of Versum Materials strengthens Merck KGaA, Darmstadt, Germany portfolio and meets group's clear financial M&A criteria

Transaction offers well-founded cost synergies driving value creation

- ▶ Due diligence completed
- ▶ ~€75m in annual run-rate cost synergies identified
- ▶ Time to realization reiterated¹: 100% by year 3, up to 50% realized in year 1
- ▶ Integration costs of €125m, spread over 2 years
- ▶ Cost synergies of 6%² of acquired net sales

Corporate / Administrative Functions

- Integrate corporate & administrative functions
- Save U.S. public company costs

Procurement / Supply Chain

- Optimize production and supply chain network
- Achieve savings through joint procurement

Business Optimization

- Transform country setup
- Streamline duplicate structures

Solid financing structure for Versum Materials acquisition secured



Financing structure secured with mix of cash and debt

- Fully committed financing is in place by way of a facilities agreement with Bank of America Merrill Lynch, BNP Paribas Fortis and Deutsche Bank
- Facilities Agreement consists of a USD 4.0bn **Bridge Loan** and a USD 2.3bn **Term Loan**
- The Bridge Loan is targeted to be taken out by a EUR **hybrid bond** as well as EUR **senior bond** offering



Strong commitment to rating reiterated


- Merck KGaA, Darmstadt, Germany has a history of **rapid deleveraging** after larger acquisitions and will continue to keep that focus
- The hybrid bond offering underpins Merck's KGaA, Darmstadt, Germany commitment to support its **strong credit ratings**

Indicative timeline to closing

Announcement
(April 12, 2019)



Closing
(Expected H2 2019)




Closing after:

Versum Materials shareholders approval¹

Regulatory approvals

Fulfillment of other customary closing conditions

Executive summary



Rebalancing group's and Performance Materials' portfolio towards high-growth markets



Creating a leading electronic materials players focused on the semiconductor and display industries



Capitalizing on attractive secular electronics industry growth trends



EPS pre accretive in first full year after closing and to reported EPS in year 3



Sustainable value creation for Merck KGaA, Darmstadt, Germany



BACK-UP

A compelling proposal for all stakeholders


A **strategically and financially compelling** transaction for Merck KGaA, Darmstadt, Germany shareholders

Delivers on strategy of **building leading positions in attractive markets**

11.6x EBITDA 2019E multiple (incl. synergies) and all cash consideration make the transaction financially attractive

Becoming an **integral part** of **leading science and technology** company Merck KGaA, Darmstadt, Germany

Commitment to maintain Tempe, Arizona presence as **the major hub** for the combined electronic materials business in the U.S.



Providing **leading-edge technology** backed by the capabilities, scale and quality of Merck KGaA, Darmstadt, Germany

Truly global footprint and **close proximity** to customers worldwide

Combines **innovation strength** to better serve our customers in a rapidly evolving marketplace


Combining the **certainty of an all-cash** transaction with an **attractive valuation**

Merck KGaA, Darmstadt, Germany – the best strategic owner of Versum Materials to the highest benefit of shareholders, employees and customers


Actively rebalances the Group portfolio for diversified, accelerated growth

Rebalancing Group portfolio to diversified structure of three strong pillars


Merck KGaA, Darmstadt, Germany
Net sales¹




Pro-forma net sales¹



Merck KGaA, Darmstadt, Germany
EBITDA pre¹



Pro-forma EBITDA pre^{1, 2}




■ Healthcare
■ Life Science
■ Performance Materials




Performance Materials and Versum Materials will have pro-forma LTM net sales of ~€3.6bn¹ and LTM EBITDA pre of ~€1.3bn^{1,2}

Performance Materials executes on its transformation program

Today³



Pro-forma⁴



■ Semiconductor Solutions
■ Display Solutions
■ Surface Solutions



Increasing exposure to high-growth market segments in electronic materials and solutions

¹LTM results as of December 31, 2018. EBITDA pre excludes Corporate & Other; ²Including 100% synergies; ³Merck KGaA, Darmstadt, Germany PM net sales for LTM Q1 2018 – Q4 2018; ⁴Pro-forma net sales consolidates Versum Materials LTM net sales as of September 30, 2018; All Versum Material's data as per Versum Materials SEC filings.

Versum Materials Financials

€m ^{1, 2}	2015	2016	2017	2018
Net sales	907	880	997	1,162
Adjusted EBITDA	271	297	329	377
Adjusted EBITDA margin	29.9%	33.7%	33.0%	32.5%
EBITDA	251	296	307	360
D&A	51	46	41	43
EBIT	200	251	266	317

robust historical financial performance

- 2015-2018 CAGR sales of ~11%
- 2015-2018 CAGR adjusted EBITDA of ~14%

¹Source: Versum Materials SEC filings; Financials converted from US\$ to EUR based on average annual exchange rate of EUR/USD; ²Versum Materials Fiscal Year ends September 30.

CONSTANTIN FEST



Head of Investor Relations
+49 6151 72-5271
constantin.fest@emdgroup.com

SVENJA BUNDSCHUH



Assistant Investor Relations
+49 6151 72-3744
svenja.bundschuh@emdgroup.com

ALESSANDRA HEINZ



Assistant Investor Relations
+49 6151 72-3321
alessandra.heinz@emdgroup.com

ANNETT WEBER



Institutional Investors /
Analysts
+49 6151 72-63723
annett.weber@emdgroup.com

AMELIE SCHRADER



Institutional Investors /
Analysts
+49 6151 72-22076
amelie.schrader@emdgroup.com

EVA STERZEL



Retail Investors / AGM /
CMDs / IR Media
+49 6151 72-5355
eva.sterzel@emdgroup.com

PATRICK BAYER



Institutional Investors /
Analysts
+49 6151 72-5642
patrick.bayer@emdgroup.com

EMAIL: investor.relations@emdgroup.com
WEB: www.emdgroup.com/investors
FAX: +49 6151 72-913321

